MorphoSys and Novartis Form Strategic Alliance

December 13, 2007
BioPharm International Editors

MorphoSys AG (Munich, Germany) and Novartis (East Hanover, NJ) have formed a comprehensive strategic alliance for the discovery and development of biopharmaceuticals.

MorphoSys AG (Munich, Germany) and Novartis (East Hanover, NJ) have formed a comprehensive strategic alliance for the discovery and development of biopharmaceuticals. The deal is aimed at establishing a pipeline of innovative drugs, and combines MorphoSys’ and Novartis’ research and development capabilities.

According to this agreement, Novartis becomes MorphoSys’s preferred collaborator for HuCAL-based drug discovery, allowing MorphoSys to progress to the next stage of its corporate development, which involves a greater focus on drug discovery and development.

Total payments under the agreement, including committed payments and milestones, could exceed $1 billion, assuming the collaboration successfully runs its maximum term.

MorphoSys releaseNovartis web site